About

Founded

2020

Headquarters

London, England, United Kingdom

Industry

Climate, Biotech

Company Description

Epoch is the Total BioDesign company developing natural solutions to unnatural problems. Combining the last thirty years of progress in computational and biological sciences we’re on a mission to scale and industrialise biology to solve our biggest climate challenges.

Quick Links

Website Jobs

Funding

Total Raised

$16 million

Valuation

Undisclosed

Significant Investors

BoxGroup, Amadeus Capital Partners, MCJ Collective, Zero Carbon Capital, VOYAGERS Climate-Tech Fund, The Venture Collective, Lowercarbon Capital

Company Traction

As of June 2023, Epoch can sequence 100 trillion enzyme variants per hour.

Leadership Team

Jacob Nathan: Co-Founder & CEO of Epoch.

Douglas Kell: Co-Founder & Chief Scientific Officer of Epoch. Former Professor at the University of Liverpool.

Beatriz Lopez: Chief People Officer at Epoch. Former Human Resources Director, EMEA at SoftBank Robotics EMEA.

James Johnson: Director of Enzyme Engineering at Epoch. Former GeneMill Facility Manager at the University of Liverpool.

Neil Swainston: Senior Computational Biologist at Epoch. Former Managing Director at GeneGenie Bioinformatics.

Press

FinSMEs (June 22, 2022): Epoch Biodesign Raises $11M in Seed Funding

Epoch